Expression Of Beclin1and LC3in Bladder Urothelial Carcinoma And Its Clinical Significance

Objective:1. To investigate Beclin1and LC3in bladder urothelial carcinoma.2. To investigate the relation between Beclin1and LC3expression and its clinicalsignificance in bladder urothelial carcinoma.Methods56cases of bladder urothelial carcinoma who were diagnosed by pathology andreceived surgery in January2008~December2012were selected, another32cases ofnormal bladder tissue were selected as control group. The level of Beclin1and LC3ofbladder urothelial carcinoma and normal bladder tissue were detected byimmunohistochemistry and Western Blot methods, then the expression differences ofthe two genes in bladder urothelial carcinoma and normal bladder tissues werecompared.Results:1. The expression level of Beclin1in bladder urothelial tissues was66.1%(37/56)which was significantly lower than93.8%in normal bladder tissue (30/32), thedifference was statistically significant (P <0.01).While the expression level of LC3incarcinoma was50%(28/56), which was also significantly lower than87.5%in normalbladder tissue (28/32), the difference was also statistically significant (P <0.01);2. The expression level of Beclin1and LC3was associated with the clinical stage of thepatients (P <0.01), and was not associated with the patient’s age, gender and tumorgrowth pattern(P>0.05); 3. The expression level of Beclin1and LC3in bladder urothelial carcinoma has apositive correlation(P <0.01).Conclusions:1.The expression level of Beclin1and LC3in bladder urothelial carcinoma was lowerthan The expression level in normal bladder tissue;2.The expression level of Beclin1and LC3are possibly concerned with thedevelopment of bladder urothelial carcinoma.